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h e i g h t v e l o c i t y and p a r t i a l GH d e f i c i e n c y i n response t o two pharmacological t e s t s (maximum peak
11 ng/ml) received GRF f o r 6 months ( 1 0 mcg/kg/day) a s a subcutaneous i n j e c t i o n ( 8 p.m.). 24-hours GH s e c r e t i o n was s t u d i e d before and a f t e r 3 months of treatment : SmC dosage and a IV GRF t e s t ( 2 mcg/kg) was done b e f o r e and a f t e r 6 months of treatment. Lower l e g length was s t ud i e d every 3 weeks by knemometry and s t a t u r a l growth a t 3 months i n t e r v a l s .
Height v e l o c i t y increased i n 5 c a s e s from 2 . 5 + 0 . 5 t o 4.4 5 1.1 cm f o r t h e 6 months period and showed no change i n 2 c a s e s . Knemometric growth r a t e i s s u b j e c t t o wide v a r i a t i o n s and is d~f -f i c u l t t o t a k e i n t o account. There was no s i g n of desensitization: 24-hour s e c r e t i o n (mx peak and I . C . ) was h i g h e r a f t e r 3 months treatment (m = 16.2 + 7 . 5 ng/ml and 3.7 + 1 . 2 ng/ml/min b e f o r e , 29 2 17.9 ng/ml and 4.5 + 2.9 ng/rnl/min a f t e r v i a -d s ) , a s was t h e GH peak i n t h e IV GRF t e s t a f t e r 6 months t r e a t m e n t (m = 36.1 ng/ml b e f o r e , 47.8 ng/ml a f t e r w a r d s ) . SmC l e v e l was h~g h e r on average a f t e r 6 months t r e a t m e n t ( 1 . 9 + 1 U/ml and 0 . 8 2 0 . 5 U / m l before t r e a t m e n t ) . The a n a l y s i s of t h e v a r i o u s p a r a n e t e r s (GH secretion, SmC) provided no elements t o account f o r the lack of therapeutic response i n the 2 c a s e s . These r e s u l t s suggest t h a t GRF treatment
CHAUSSAIN) -I n s t i t u t R.B. GREENBLATT -BORDEAUX and SANOFI-RECHERCHE -MONTPELLIER (FRANCE) EFFECTS OF GROWTH-HORMONE -RELEASING HORMONE (GRF) I N 5 CHILDREN WITH IMPAIRED GROWTH HORMONE (GH) SECRETION.
5 c h i l d r e n (8.24+/-3.63 y e a r s ) w i t h growth r e t a r d a t i o n (3.4 +/-0.9 DS)bone age r e t a r d a t i o n (3.13+/-2.40 y e a r s ) and i n s u ff i c i e n t growth v e l o c i t y (3.9+/-0.6 cm/year) r e l a t e d w i t h complet e (n=2) o r p a r t i a l (n=3) GH d e f i c i e n c y were t r e a t e d w i t h a d a il y dose of 300 mcg GRF administred subcutaneously (SC)every o t h e r week f o r a 6 months period. GH response t o SC GRF administ r a t i o n , GH and GRF a n t i b o d i e s and somatomedins were studied on repeated blood samples performed on day 1 and day 8 of t h e f i r s t week of treatment a s w e l l a s a t t h e end of the 6 months therapy. Growth v e l o c i t y increased t o 6.16+/-1.17 cmlyear. 3 of the 5 p a t i e n t s have a c c e l e r a t e d growth mainly f o r t h e f i r s t 3 months. Linear growth was increased i n complete (c2.5 and 4.3 cm/year) more than i n p a r t i a l (+0.4, +0.8 and + 3 . 3 cmlyear) GH d e f i c i e n t c h i l d r e n . The a r e a under t h e GH curve a f t e r GRF a d m i n i s t r a t i o n was 1050.7+/-767.7 on day 1 , 472.1+/-103.2 on day 8 and 631.9 +/-148.1 ng/ml x min. a f t e r 6 months therapy. No major change i n o t h e r hormonal e v a l u a t i o n s was noted.
These r e s u l t s confirm t h a t GRF can s t i m u l a t e l i n e a r growth i n some GH d e f i c i e n t c h i l d r e n and lead t o d i s c u s s t h e r o l e of l im i t i n g f a c t o r s i n i t s long term e f f e c t s such a s d e s e n s i t i z a t i o n , a n t i b o d i e s o r s o m a t o s t a t i n .
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PULSATI1,E GROWTH HORMONE RELEASING HORMONE TREATMENT OF GH DEFICIENCY We have t r e a t e d 11 p r e p u b e r t a l c h i l d r e n ( 7~; 4~) w i t h i d i o p a t h i c G H d e f i c i e n c y due t o p i t u i t a r y hypoplasia u s i n g
GHRH 1-40. This was administered subcutaneously f o r 4 p u l s e s a t 3 h o u r l y i n t e r v a l s a t n i g h t i n a dose of 1-2figlkg/pulse. Blood samples f o r G H c o n c e n t r a t i o n s were taken a t 20 minute i n t e r v a l s f o r 24 hours b e f o r e treatment and throughout t h e study monthly a t n i g h t .
P
u l s a t i l e G H s e c r e t i o n was induced i n 10 c h i l d r e n from t h e f i r s t n i g h t of t r e a t m e n t and t h e response augmented w i t h time.
Growth v e l o c i t y i n 8 of 11 c h i l d r e n i n c r e a s e d from 3.3cmIyr (range 1.7 t o 4.9) b e f o r e t r e a t m e n t t o 6.9cmIyr (range 5-8.5) on GHRH. 2 c h i l d r e n had no change i n h e i g h t v e l o c i t y and one had a p r o g r e s s i v e diminution of CH s e c r e t i o n and a f a l l i n growth v e l o c i t y .
GHRH ( l u g l k g ) was a l s o administered i n t r a v e n o u s l y t o a l l c h i l d r e n b e f o r e treatment and a t 3 monthly i n t e r v a l s . Although a GH response was seen on a l l o c c a s i o n s , t h e responses p r e d i c t e d n e i t h e r t h e GH c o n c e n t r a t i o n s n o r the growth v e l o c i t i e s obtained on long term s . c . t r e a t m e n t . P u l s a t i l e a d m i n i s t r a t i o n of GHRH 1-40 was e f f e c t i v e i n inducing GH s e c r e t i o n and promoting growth a c c e l e r a t i o n i n t h e m a j o r i t y of c h i l d r e n w i t h i d i o p a t h i c G H d e f i c i e n c y . may be considered a s a t h e r a p e u t i c a l t e r n a t i v e i n GH d e f i c i e n c~e s . 
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